Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
RANIthis companyRani Therapeutics Holdings, Inc.	$0.57	-3×	2.7×	54.68×	-2.02×	-41.3%	44.9%	-2346.0%	-1817.1%	-89.9%	-80.6%	-21.1%	0.13×	0.38×	-13.25×	4.21×	0.0%	5	-2.49	2	C
CRBPCorbus Pharmaceuticals Holdings, Inc.	$3.47	-1.38×	0.73×	0×	-1.04×	-49.7%	0.0%	0.0%	0.0%	-53.2%	-57.2%	-59.5%	0.01×	0.34×	0×	8.07×	0.0%	1	-6.62	2	B-
CRDFCardiff Oncology, Inc.	$0.81	-4.07×	4.14×	316.73×	-3.81×	-96.7%	100.0%	-8256.3%	-7732.0%	-101.0%	-105.9%	-20.2%	0.02×	0.37×	0×	3.67×	0.0%	2	-16.02	2	C
ELTXElicio Therapeutics, Inc.	$1.63	-3.09×	74.5×	0×	-3.16×	-85.8%	0.0%	0.0%	0.0%	-2418.8%	-201.0%	-30.3%	8.87×	0.11×	-33.29×	2.38×	0.0%	2	-14.29	1	D+
TNXPTonix Pharmaceuticals Holding Corp.	$4.51	-1.07×	0.54×	10.14×	0.6×	373.2%	34.7%	-959.1%	-946.2%	-50.6%	-51.0%	-77.6%	0.01×	1.69×	-1,412.39×	7.42×	0.0%	3	-4.63	3	B
Peer median	—	-2.23×	2.44×	5.07×	-2.1×	-67.7%	17.3%	-479.5%	-473.1%	-77.1%	-81.6%	-44.9%	0.01×	0.36×	-16.64×	5.54×	0.0%	2	-10.46	2	—